Not applicableActive Not RecruitingNCT02633111
What this trial is testing
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Who this might be right for
B-cell Non-Hodgkin LymphomaAggressive
Memorial Sloan Kettering Cancer Center 501